Last updated: June 22, 2026
ABBVIE INC. v. MSN PHARMACEUTICALS INC. (3:26-cv-00115): Litigation Summary, Claims in Dispute, and Patent-Entry Exposure
Executive summary: No complete, case-specific litigation record is available in the provided input for AbbVie Inc. v. MSN Pharmaceuticals Inc., case No. 3:26-cv-00115. Without the complaint, asserted patent list, ANDA/Paragraph IV identifiers, district court docket entries, or settlement order, a complete and accurate litigation summary and patent-strength analysis cannot be produced.
What does the AbbVie v. MSN Pharmaceuticals 3:26-cv-00115 complaint allege?
A litigation summary requires the complaint’s core elements: parties, court, active patents, infringement theory, ANDA/marketing exclusivity posture, and the specific relief sought (injunctive relief under 35 U.S.C. § 271(e)(2) and 21 U.S.C. § 355(j)). Those allegations are not present in the provided material, so the asserted patent claims and the infringement framework cannot be stated.
Which patents are asserted in AbbVie Inc. v. MSN Pharmaceuticals Inc. (3:26-cv-00115)?
A correct patent estate mapping depends on the asserted patent numbers and expiration dates tied to the complaint. The case identifier alone does not contain the asserted patent list.
What patents protect the AbbVie product at issue in 3:26-cv-00115?
A product-level protection assessment requires knowing the drug (active ingredient, dosage form, strength) and whether the case targets:
- composition/formulation patents
- method-of-use patents
- manufacturing/process patents
- polymorph/crystal patents
- REMS or device-linked claims
No drug name or patent list is provided.
What formulations are protected by the asserted patents in this case?
Formulation scope analysis requires claim language, dosage form, and the asserted patent specifications or claim charts. None are provided.
What method-of-use patents are implicated, if any?
Method-of-use claim analysis requires the asserted use claims, indication, and dosing regimens. None are provided.
When does exclusivity end and when could generic entry occur after 3:26-cv-00115?
Generic entry timing analysis needs at minimum:
- the branded product’s FDA exclusivity end dates
- Orange Book exclusivity codes and listed patents
- the ANDA filing date and the 180-day exclusivity posture
Those inputs are not included.
Is this dispute a Paragraph IV ANDA challenge, biosimilar dispute, or something else?
A litigation-characterization section must identify whether MSN is challenging listed patents in an ANDA (Paragraph IV) under 35 U.S.C. § 271(e)(2), or whether the case is tied to a 505(b)(2) pathway, biologics pathway, or other regulatory vehicle. The provided case reference contains no such details.
What Paragraph IV challenges are being asserted in AbbVie v. MSN Pharmaceuticals Inc.?
A Paragraph IV section must state:
- which patents were certified
- whether certifications are Paragraph IV, I, II, III, or V
- the carved-out grounds (non-infringement, invalidity) and the technical basis
None of that is available.
How does the patent expiration and term-adjustment timeline affect the litigation strategy?
Term and exclusivity timing analysis requires:
- patent issue dates, expiration dates, and PTA
- patent family structure
- whether the patents are subject to terminal disclaimers
No patent data is provided.
What is the Orange Book status of the relevant AbbVie patents in 3:26-cv-00115?
Orange Book status requires the branded drug name, listing dates, patent numbers, and exclusivity codes. Those inputs are not present.
What settlement, consent judgment, or stipulation outcomes exist in 3:26-cv-00115?
Outcome analysis depends on docket entries: settlement agreements, stipulated dismissals, consent injunctions, or court orders. None are provided.
What generic entry risks exist for MSN Pharmaceutical after this case?
Entry-risk assessment requires:
- whether infringement findings occurred
- whether a court stayed enforcement
- whether a workaround label or design-around exists
- whether final judgment or appeal timing shifts launch
No procedural posture is provided.
How strong is the patent estate for the AbbVie product involved in this litigation?
A strength analysis requires claim construction history (if any), asserted claim types, obviousness/invalidity grounds, and prior art set. None is available.
Does the litigation hinge on novelty, obviousness, or non-infringement?
That breakdown is based on the invalidity defenses and claim charts. Not provided.
What manufacturing/IP barriers could delay FDA approval or commercial launch?
Manufacturing/IP barriers depend on:
- whether patents target manufacturing steps or intermediates
- whether there are process licensing constraints
- whether FDA approval was blocked by litigation stays
No product/patent scope is provided.
Which companies are co-litigants or interested parties in this case?
A credible comparison requires co-plaintiffs, co-defendants, ANDA applicants, and any related litigations. None is provided.
How does AbbVie v. MSN compare with other recent AbbVie patent litigations?
Comparative analysis requires at least one known comparator: patents asserted, outcomes, or settlement terms from similar AbbVie cases. None are provided, and no branded product is identified.
Key takeaways
No case-specific litigation summary, patent assertions, exclusivity implications, or entry-risk analysis can be completed from the provided input alone.
FAQs
- What docket documents are required to produce an accurate litigation summary for a patent case like 3:26-cv-00115?
- How do Paragraph IV certifications map to asserted patent infringement and invalidity theories?
- What data from the Orange Book and FDA exclusivity listings drives generic launch timing analysis?
- How are settlement terms typically reflected in consent judgments or stipulated dismissals in ANDA cases?
- What claim types most often determine infringement outcomes in pharma patent litigations?
References
- PACER / U.S. District Court docket, case No. 3:26-cv-00115 (AbbVie Inc. v. MSN Pharmaceuticals Inc.).
